Payment overview · 2025
General Payments
$1,389.39
20 reported records · 5 companies
Healthcare provider profile · identity verified
Kee Yee Shum, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · FLUSHING, NY · NPI 1629146196
Verified facts
What the public records show
CMS Open Payments records show Kee Yee Shum, MD received $1,389.39 in general payments during 2025 across 20 reported records.
Janssen Biotech, Inc. accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Opdivo, Tagrisso.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Tagrisso by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPDIVO as an associated drug or biological on 20448 records involving 6494 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Opdivo by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $582.47 | 41.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $378.63 | 27.2% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $309.85 | 22.3% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $109.19 | 7.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $9.25 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,280.19 | 18 |
| Education | $109.20 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $482.52 | 4 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $482.52 | 4 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $293.47 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $109.19 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $99.95 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $92.08 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $42.66 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OPDIVO opdivo |
2025 | Opdivo | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 93 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
93 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | OPDIVO open payments reported associated product |
CMS Open Payments — General Payments 20448 supporting records · 6494 recipient NPIs · example record 1184377705 |
Opdivo · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 619 | 166 |
| Atorvastatin Calcium | Atorvastatin Calcium | 571 | 160 |
| Losartan Potassium | Losartan Potassium | 400 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 97 |
| Omeprazole | Omeprazole | 282 | 97 |
| Meloxicam | Meloxicam | 245 | 99 |
| Metformin Hcl | Metformin Hcl | 236 | 64 |
| Simvastatin | Simvastatin | 208 | 50 |
| Valsartan | Valsartan | 195 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 45 |
| Raloxifene Hcl | Raloxifene Hcl | 161 | 38 |
| Azithromycin | Azithromycin | 136 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 41 |
| Alendronate Sodium | Alendronate Sodium | 131 | 32 |
| Letrozole | Letrozole | 117 | 25 |
| Allopurinol | Allopurinol | 110 | 32 |
| Metformin Hcl Er | Metformin Hcl | 106 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 102 | 56 |
| Glimepiride | Glimepiride | 93 | 21 |
| Tagrisso | Osimertinib Mesylate | 93 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 85 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 68 |
| Furosemide | Furosemide | 74 | 35 |
| Montelukast Sodium | Montelukast Sodium | 73 | 26 |
| Atenolol | Atenolol | 72 | 22 |
| Finasteride | Finasteride | 72 | 21 |
| Trazodone Hcl | Trazodone Hcl | 71 | 18 |
| Nifedipine Er | Nifedipine | 69 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 15 |
| Januvia | Sitagliptin Phosphate | 65 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 14 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 54 | suppressed |
| Cefdinir | Cefdinir | 50 | 48 |
| Gabapentin | Gabapentin | 49 | 20 |
| Lisinopril | Lisinopril | 48 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 23 |
| Tasigna | Nilotinib Hcl | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 15 |
| Retacrit | Epoetin Alfa-Epbx | 45 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Hydroxyurea | Hydroxyurea | 42 | 14 |
| Procrit | Epoetin Alfa | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 12 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 39 | suppressed |
| Telmisartan | Telmisartan | 38 | suppressed |
| Carvedilol | Carvedilol | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 11 |
| Eliquis | Apixaban | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 16 |
| Keytruda | Pembrolizumab | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Xgeva | Denosumab | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Stivarga | Regorafenib | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 12 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lupron Depot | Leuprolide Acetate | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Opdivo | Nivolumab | 23 | suppressed |
| Truxima | Rituximab-Abbs | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 12 |
| Tamoxifen Citrate | Tamoxifen Citrate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Xtandi | Enzalutamide | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Pemetrexed Disodium | Pemetrexed Disodium | 18 | suppressed |
| Entecavir | Entecavir | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Imbruvica | Ibrutinib | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Oxaliplatin | Oxaliplatin | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Abraxane | Paclitaxel Protein-Bound | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 12 |
| Naproxen | Naproxen | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,389.39 · 20 records | Janssen Biotech, Inc. | CARVYKTI, ERLEADA, IMFINZI, KISUNLA, OPDIVO, RYBREVANT, TAGRISSO | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Opdivo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error